Safety Study of ALG- 1001 to Treat Diabetic Macular Edema
NCT ID: NCT01482871
Last Updated: 2012-12-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE1/PHASE2
INTERVENTIONAL
2011-01-31
2011-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1.5 mg ALG-1001
Group Using 1.5 mg per 100 ul of ALG-1001
ALG-1001
1.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
Arm 2.5 mg ALG-1001
Group Using 2.5 mg per 100 ul of ALG-1001
ALG-1001
2.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
Arm 5.0 mg ALG-1001
Group Using 5.0 mg per 100 ul of ALG-1001
ALG-1001
5.0 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
Arm 7.5 mg ALG-1001
Group Using 7.5 mg per 100 ul of ALG-1001
ALG-1001
7.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ALG-1001
1.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
ALG-1001
2.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
ALG-1001
5.0 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
ALG-1001
7.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patient (male or female) with active diabetic macular edema (DME).
3. Patient whose study eye has a best corrected visual acuity (BCVA) of 20/50 to 20/160 ETDRS equivalent (65 letters to 36 letters), that in the opinion of the investigator is primarily due to DME will be intravitreally injected with 0.10 cc containing 1.5mg/100µl or 2.5mg/100µl of ALG-1001. Decrease in BCVA must be assessed based on clinical exploration, macular thickening, presence of clinical significant macular edema and/or OCT findings consistent with diabetic macular edema.
4. Patient whose study eye has a best corrected visual acuity (BCVA) of 20/200 or worse ETDRS equivalent (35 letters or less), that in the opinion of the investigator is primarily due to DME will be intravitreally injected with 0.10 cc containing 5.0mg/100µl or 7.5mg/100µl of ALG-1001. Decrease in BCVA must be assessed based on clinical exploration, macular thickening, presence of clinical significant macular edema and/or OCT findings consistent with diabetic macular edema.
5. Patients Intra-Ocular Pressure (IOP) is under control, IOP ≤ 25 mm
6. Patient is willing and able to return for all study visits.
7. Patient is able to meet the extensive post-op evaluation regimen
8. Patient can understand and sign Informed Consent form.
Exclusion Criteria
2\. Patients with active Proliferative Diabetic Retinopathy (PDR) in the study eye such as NVE, NVD, Vitreous Hemorrhage, or Neovascular Glaucoma.
3\. Patients with current or prior Retinal Detachments, Retinal tears, or Tractional Detachments in either eye.
4\. Patients with significant epiretinal membranes determined by the investigator to be contributing to the macular edema.
5\. Patients with other retinal pathologies that would interfere with their vision.
6\. Patient that has Chronic or Recurrent Uveitis. 7. Patient that has undergone Vitrectomy (anterior or pars plana) in the study eye.
8\. Patient has ongoing Ocular infection or inflammation in either eye. 9. Patient has a history of intravitreal injections of any type in the study eye within the last 45 days prior to study enrollment.
10\. Patient has a history of focal laser of any type in the study eye within the last 90 days prior to study enrollment.
11\. Patient has a history of cataract surgery complications/vitreous loss in the study eye.
12\. Patient has congenital eye malformations in the study eye. 13. Patient has a history of penetrating Ocular Trauma in the study eye. 14. Patient is mentally handicapped. 15. Patient is Pregnant or Nursing female. If subject is 18 to 60 years old. Negative pregnancy test during the screening window.
16\. Patient that is currently participating in any other Clinical Research Study 17. Patient has contraindication to the study medication.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allegro Ophthalmics, LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hugo Quiroz, M.D
Role: PRINCIPAL_INVESTIGATOR
Denver Medical Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Apec Hospital La Ceguera
Mexico City, , Mexico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Focus 2
Identifier Type: -
Identifier Source: org_study_id